DDInter895 DDInter927
Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect. Hydroxyzine is also used for generalized anxiety disorder, tension caused by psychoneurosis, and other conditions with manifestations of anxiety.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Hydroxyzine {u} (Compound) resembles {v} (Compound) Anileridine
Hydroxyzine {u} (Compound) resembles {v} (Compound) Quetiapine
Hydroxyzine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyclizine
Hydroxyzine {u} (Compound) binds {v} (Gene) HRH1
Hydroxyzine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine Receptor Antagonists
Hydroxyzine {u} (Compound) causes {v} (Side Effect) Drowsiness
Hydroxyzine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Hydroxyzine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hyaluronidase
Hydroxyzine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Terfenadine
Hydroxyzine {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Hydroxyzine (Compound) resembles Anileridine (Compound)
Hydroxyzine (Compound) resembles Quetiapine (Compound)
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Hydroxyzine (Compound) binds HRH1 (Gene)
Hydroxyzine (Compound) is included by Histamine Receptor Antagonists (Pharmacologic Class)
Hydroxyzine (Compound) causes Drowsiness (Side Effect)
Hydroxyzine may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Hydroxyzine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine
Hydroxyzine may lead to a major life threatening interaction when taken with Macimorelin